Svetinorm
Research OnlyA cytamin-class peptide supplement derived from liver tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for liver health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Liver cytamin · Hepatic peptides · A-4 liver peptides
Preclinical evidence only
- Preclinical
- 83%
- Clinical
- 0%
Based on 6 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 13: animal + in-vitro evidence only for the liver-peptide program, zero human studies for svetinorm itself (1A animal-no-human 6, 1B high-RoB preclinical 2, 1C human N=0 → 0, 1D indirect surrogate explant/animal endpoints 2, 1E modest single-group preclinical base 3). Mechanism 25: svetinorm is an undefined tissue-derived cytamin mixture — target inferred via the Khavinson tissue-specificity framework but no binding/affinity data (2A 10), proximal organotypic-explant signaling only partly characterized (2B 8), no dose-response for the complex (2C 2), some in-vivo rat data for defined congeners not the mixture (2D 5). Plausibility 52: liver-support claim is class-coherent (Livagen/KEDA and Ventvil/Hepalin show analogous liver-explant stimulation, 11713572/12096446) but rests on an unproven oral- bioavailability link for an undefined peptide complex (3A 15, 3B 14, 3C 12, 3D tightly scoped single-organ 11). Global Coverage 13: all evidence from one Russian group (St. Petersburg/Chita, Khavinson), no independent replication or non-Russian work, <5 directly relevant studies, no regulator approval as a drug (4A 4, 4B 4, 4C 5, 4D 0). Community Experience 16: dossier reports no meaningful user discussion — negligible documented use, no consistency or adverse signal to assess (5A 4, 5B 7, 5C 0, 5D 5). Effectiveness not-established: no quantified human efficacy estimate and no meaningful community effect signal. Evidence sourced from PubMed (Khavinson liver- peptide program: PMIDs 32362099, 12096446, 11713572, 12374906).
Mechanism of Action
Svetinorm is a cytamin-class supplement containing peptide complexes derived from liver tissue.
Proposed Mechanisms
- Hepatocyte Support - Claimed to support liver cell function
- Detoxification - Proposed effects on liver metabolic pathways
- Regeneration - Marketed to support liver tissue renewal
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials
- NOT a treatment for liver disease
- Not approved by any Western regulatory agency
Livagen
CompatibleBoth target liver function - Livagen is synthetic KED tripeptide, Svetinorm is tissue-derived cytamin supplement.
Ovagen
CompatibleBoth target liver - Ovagen is synthetic EDL tripeptide, Svetinorm is tissue-derived complex.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Svetinorm
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.